Suramin sensitizes cells to ionizing radiation by inactivating DNA-dependent protein kinase

Radiation Research

Volumn 162, Issue 3, 2004, Pages 308-314

  Hosoi, Yoshio ^a,b   Matsumoto, Yoshihisa ^a   Enomoto, Atsushi ^a   Morita, Akinori ^a   Green, Joseph ^b   Nakagawa, Keiichi ^a   Naruse, Kiyoshi ^a   Suzuki, Norio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; SURAMIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RADIOSENSITIZING AGENT;

ARTICLE; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; X RAY; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FIBROBLAST; METABOLISM; NEOPLASM; PATHOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; TUMOR CELL LINE; ULTRAVIOLET RADIATION;

CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SURAMIN; ULTRAVIOLET RAYS; X-RAYS;

EID: 4644327948     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3217     Document Type: Article

References (48)

1. C. A. Stein, Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53, 2239-2248 (1993).
2. S. Broder, R. Yarchoan, J. M. Collins, H. C. Lane, P. D. Markham, R. W. Klecker, R. R. Redfield, H. Mitsuya, D. F. Hoth and E. Gelmann, Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo. Lancet 2, 627-630 (1985).
3. M. Kaur, E. Reed, O. Sartor, W. Dahut and W. D. Figg, Suramin's development: What did we learn? Invest. New Drugs 20, 209-219 (2002).
4. M. Hosang, Suramin binds to platelet-derived growth factor and inhibits its biological activity. J. Cell. Biochem. 29, 265-273 (1985).
5. R. J. Coffey, Jr., E. B. Leof, G. D. Shipley and H. L. Moses, Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol. 132, 143-148 (1987).
6. M. Pollak and M. Richard, Suramin blockade of insulin like growth factor I-stimulated proliferation of human osteosarcoma cells. J. Natl. Cancer Inst. 82, 1349-1352 (1990).
7. G. B. Mills, N. Zhang, C. May, M. Hill and A. Chung, Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res. 50, 3036-3042 (1990).
8. R. Huffman and L. Cameron, Characterization of a scintillation proximity assay to detect modulators of transforming growth factor alpha (TGF alpha) binding. Anal. Biochem. 203, 70-75 (1992).
9. C. P. Minniti, M. Maggi and L. J. Helman, Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 52, 1830-1835 (1992).
10. G. Strassmann, M. Fong, C. E. Freter, S. Windsor, F. D'Alessandro and R. P. Nordan, Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Invest. 92, 2152-2159 (1993).
11. J. W. Russell, A. J. Windebank and J. L. Podratz, Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann. Neurol. 36, 221-228 (1994).
12. P. Leland, N. Obiri, B. B. Aggarwal and R. K. Puri, Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response. Oncol. Res. 7, 227-235 (1995).
13. J. Waltenberger, U. Mayr, H. Frank and V. Hombach, Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J. Mol. Cell. Cardiol. 28, 1523-1529 (1996).
14. M. Kandefer-Szerszen, K. Ruuth and E. Lundgren, Effect of suramin on human interferon alpha binding to cell receptors. Arch. Immunol. Ther. Exp. 45,93-99 (1997).
15. Z. Spigelman, A. Dowers, S. Kennedy, D. DiSorbo, M. O'Brien, R. Barr and R. McCaffrey, Antiproliferative effects of suramin on lymphoid cells. Cancer Res. 47, 4694-4698 (1987).
16. C. W. Mahoney, A. Azzi and K. P. Huang, Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J. Biol. Chem. 265, 5424-5428 (1990).
17. K. Bojanowski, S. Lelievre, J. Markovits, J. Couprie, A. Jacquemin-Sablon and A. K. Larsen, Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA 89, 3025-3029 (1992).
18. Y. L. Zhang, Y. F. Keng, Y. Zhao, L. Wu and Z. Y. Zhang, Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 273, 12281-12287 (1998).
19. H. Mitsuya, M. Popovic, R. Yarchoan, S. Matsushita, R. C. Gallo and S. Broder, Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226, 172-174 (1984).
20. L. Yakubov, Z. Khaled, L. M. Zhang, A. Truneh, V. Vlassov and C. A. Stein, Oligodeoxynucleotides interact with recombinant CD4 at multiple sites. J. Biol. Chem. 268, 18818-18823 (1993).
21. C. A. Stein, Does antisense exist? Nat. Med. 1, 1119-1121 (1995).
22. Y. Hosoi, Y. Matsumoto, M. Tomita, A. Enomoto, A. Morita, K. Sakai, N. Umeda, H-J. Zao, K. Nakagawa and N. Suzuki, Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity. Br. J. Cancer 86, 1143-1149 (2002).
23. Y. Hosoi, H. Miyachi, Y. Matsumoto, H. Ikehata, J. Komura, K. Ishii, H. J. Zhao, M. Yoshida, Y. Takai and T. Ono, A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation. Int. J. Cancer 78, 642-647 (1998).
24. J. P. Murnane, Inducible gene expression by DNA rearrangements in human cells. Mol. Cell. Biol. 6, 549-558 (1986).
25. N. J. Finnie, T. M. Gottlieb, T. Blunt, P. A. Jeggo and S. P. Jackson, DNA-dependent protein kinase activity is absent in xrs-6 cells: Implications for site-specific recombination and DNA double-strand break repair. Proc. Natl. Acad. Sci. USA 92, 320-324 (1995).
26. J. D. Dignam, R. M. Lebovitz and R. G. Roeder, Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475-1489 (1983).
27. K. Sakata, Y. Matsumoto, H. Tauchi, M. Satoh, A. Oouchi, H. Nagakura, K. Koito, Y. Hosoi, N. Suzuki and M. Hareyama, Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int. J. Radiat. Oncol. Biol. Phys. 49, 161-167 (2001).
28. H. Wang, Z. C. Zeng, T. A. Bui, S. J. DiBiase, W Qin, F. Xia, S. N. Powell and G. Iliakis, Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. Cancer Res. 61, 270-277 (2001).
29. R. Okayasu, K. Suetomi and R. L. Ullrich, Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells. Radiat. Res. 149, 440-445 (1998).
30. J. A. Longo, B. Nevaldine, S. L. Longo, J. A. Winfield and P. J. Hahn, An assay for quantifying DNA double-strand break repair that is suitable for small numbers of unlabeled cells. Radiat. Res. 147, 35-40 (1997).
31. K. A. Biedermann, J. R. Sun, A. J. Giaccia, L. M. Tosto and J. M. Brown, seid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc. Natl. Acad. Sci. USA 88, 1394-1397 (1991).
32. W. K. Sinclair and R. A. Morton, X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res. 29, 450-474 (1966).
33. S. Olivier, P. Formento, J. L. Fischel, M. C. Etienne and G. Milano, Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur. J. Cancer 26, 867-871 (1990).
34. A. Lokshin, X. Peng, P. G. Campbell, A. Barsouk and M. L. Levitt, Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines. Cancer Chemother. Pharmacol. 43, 341-347 (1999).
35. 125I-epidermal growth factor binding to human meningiomas. Cell. Mol. Neurobiol. 13, 665-675 (1993).
36. C. Myers, M. Cooper, C. Stein, R. LaRocca, M. M. Walther, G. Weiss, P. Choyke, N. Dawson, S. Steinberg and M. M. Uhrich, Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 10, 881-889 (1992).
37. P. R. Hutson, K. D. Tutsch, R. Rago, R. Arzoomanian, D. Alberti, M. Pomplun, D. Church, R. Marnocha, A. L. Cheng and G. Wilding, Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin. Cancer Res. 4, 1429-1436 (1998).
38. S. Baghdiguian, J. L. Boudier, J. A. Boudier and J. Fantini, Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: A study by quantitative autoradiography. Eur. J. Cancer 32A, 525-532 (1996).
39. A. R. Gagliardi, M. F. Taylor and D. C. Collins, Uptake of suramin by human microvascular endothelial cells. Cancer Lett. 125, 97-102 (1998).
40. O. Hammarsten and G. Chu, DNA-dependent protein kinase: DNA binding and activation in the absence of Ku. Proc. Natl. Acad. Sci. USA 95, 525-530 (1998).
41. C. Y. Chiu, R. B. Gary, D. J. Chen, S. R. Peterson and P. L. Stewart, Cryo-EM imaging of the catalytic subunit of the DNA-dependent protein kinase. J. Mol. Biol. 284, 1075-1081 (1998).
42. K. K. Leuther, O. Hammarsten, R. D. Kornberg and G. Chu, Structure of DNA-dependent protein kinase: implications for its regulation by DNA. EMBO J. 18, 1114-1123 (1999).
43. A. G. Polischouk, B. Cedervall, S. Ljungquist, J. Flygare, D. Hellgren, R. Grenman and R. Lewensohn, DNA double-strand break repair, DNA-PK, and DNA ligases in two human squamous carcinoma cell lines with different radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 43, 191-198 (1999).
44. S. Omori, Y. Takiguchi, A. Suda, T. Sugimoto, H. Miyazawa, Y. Takiguchi, N. Tanabe, K. Tatsumi, H. Kimura and T. Kuriyama, Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair 1, 299-310 (2002).
45. A. Sak, M. Stuschke, R. Wurm, G. Schroeder, B. Sinn, G. Wolf and V. Budach, Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: Consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res. 62, 6621-6624 (2002).
46. S. J. Collis, M. J. Swartz, W. G. Nelson and T. L. DeWeese, Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 63, 1550-1554 (2003).
47. I. Ader, C. Muller, J. Bonnet, G. Favre, E. Cohen-Jonathan, B. Salles and C. Toulas, The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene 21, 6471-6479 (2002).
48. I. Ader, C. Toulas, F. Dalenc, C. Delmas, J. Bonnet, E. Cohen-Jonathan and G. Favre, RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21, 5998-6006 (2002).